/
Unless the context otherwise requires, references in this Business section to ADMA, ADMA Biologics, the Company, we, us and our refer to ADMA Biologics, Inc., a Delaware corporation, as well as its wholly owned subsidiaries, ADMA BioManufacturing, LLC, a Delaware limited liability company ( ADMA BioManufacturing ), ADMA BioCenters Georgia Inc., a Delaware corporation ( ADMA BioCenters ) and ADM…
$8.71
$0.10 (-1.14%)
EOD Jul 17, 2026
Margins and capital returns are both well above average: 37.53% operating margin, ROIC at 31.51%. Consistent with durable pricing power, though that alone doesn't make it a buy.
Revenue up 19.6% YoY with margins expanding 4.9pp. However, free cash flow softened 75%, worth monitoring whether this is timing or structural.
Free cash flow declined 75% versus the prior year, cash generation momentum has weakened. ROIC dropped from 38.05% to 31.51%, capital efficiency is deteriorating.
12.8x earnings, 19.4x FCF. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$510M
▲ +19.6% YoY
Net Income (TTM)
$165M
▼ -25.7% YoY
Op. Margin
42.14%
▲ +4.9pp YoY
ROIC
33.51%
▼ -6.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$108M
▼ -74.8% YoY
Op. Cash Flow (TTM)
$128M
▼ -57.5% YoY
Net Debt
$66M
Cash & Equiv.
$138M
5Y CAGR: +64.6%
Continue Research
At a P/E of 12.8 and a price-to-free-cash-flow of 19.4, Adma Biologics (ADMA) trades below a two-stage DCF intrinsic value of about $22.42 per share, so at $8.71 the stock looks undervalued (157.4% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Adma Biologics scores 84/100 on Intrinsiqq's quality scorecard (a high-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $22.42 per share for ADMA, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $16.82. At today's $8.71, that puts the stock about 157.4% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Adma Biologics scores 84 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a high-quality business on these measures. Recent fundamentals include a 42.1% operating margin and a 33.5% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. ADMA currently trades below its estimated intrinsic value and scores 84/100 on quality (high-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.